Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Allarity Therapeutics (ALLR) EBITDA Margin (2024 - 2025)

Allarity Therapeutics' EBITDA Margin history spans 2 years, with the latest figure at 3544.07% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 594127.0% year-over-year to 3544.07%; the TTM value through Dec 2025 reached 6430.81%, up 268533.0%, while the annual FY2025 figure was 3718.12%, N/A changed from the prior year.
  • EBITDA Margin reached 3544.07% in Q4 2025 per ALLR's latest filing, down from 4645.61% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 34583.33% in Q2 2025 to a low of 416.2% in Q2 2024.